SOAT1 and acute lymphoblastic leukemia: Therefore, those genes involved in oncogenesis and upregulated as a consequence of JAK/STAT pathway mutations may become potential therapeutic targets for the development of novel personalized therapies against a relevant fraction of T-ALL cases.